enGene Therapeutics Inc.

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs. Its lead product candidate, detalimogene voraplasmid, is being developed as a monotherapy for non-muscle invasive bladder cancer, including difficult-to-treat high-risk cases. enGene Therapeutics Inc. also advances a broader pipeline of gene therapy programs aimed at localized treatment delivery in oncology and other therapeutic areas. Based in Montreal, Canada, the company plays a specialized role in the biotechnology market by pursuing tissue-targeted genetic therapies that seek to address complex diseases through precision delivery approaches.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Ronald H. W. Cooper

Employees

81

Headquarters

Montreal, QC, Canada

Website

www.engene.com